Expansion Timeline Revised Amid Market Conditions
Rossari Biotech has announced that its subsidiaries, Unitop Chemicals and Tristar Intermediates, will reschedule planned capacity expansion projects due to evolving business requirements and prevailing market conditions.
According to the company, the implementation of the projects will now be phased over the next two years. Rossari emphasized that the revised timeline does not alter its long-term strategic investment objectives and reflects a measured approach to capacity deployment.
The company stated that it remains committed to future growth despite the adjusted schedule.
Capacity Addition Plans Remain in Place
Under previously announced plans, Unitop Chemicals was expected to add 18,500 tonnes per annum (TPA) of capacity by Q4 FY26 with an investment of approximately ₹77 crore.
Tristar Intermediates had planned to add 3,600 TPA through an investment of around ₹20 crore, targeting commissioning during FY26.
Rossari noted that the projects remain part of its broader expansion strategy, with only the implementation timeline being revised.
Implications for the Specialty Chemicals Sector
The development highlights the cautious investment approach being adopted by specialty chemical manufacturers amid changing market dynamics and demand conditions.
An earlier expansion plan announced in 2023 for Rossari’s Dahej facility and Unitop Chemicals involved a combined capacity increase of 50,000 TPA with a planned investment of ₹178 crore.
Unitop Chemicals and Tristar Intermediates play an important role in Rossari’s specialty chemicals portfolio, serving industries including:
- Home care
- Personal care
- Textiles
- Industrial applications
For suppliers and customers across these sectors, the announcement reflects ongoing efforts by manufacturers to align capital expenditure and capacity additions with evolving market requirements while maintaining long-term growth plans.